Stonebridge Capital Advisors’s Entera Bio ENTX Stock Holding History

Stonebridge Capital Advisors’s Portfolio ENTX Stock Details ENTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-200	Closed	-$145	–	399
2023 Q3	$145	Buy	+200	New	+$147	﹤0.01%	903

Other funds holding ENTX

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Stonebridge Capital Advisors's ENTX Position: Q4 2023 in Review

Stonebridge Capital Advisors sold out of Entera Bio (ENTX) in Q4 2023, closing a stake of 200 shares — an estimated $145 sold.

Stonebridge Capital Advisors first reported a position in ENTX in Q3 2023 and held it in 1 quarter. The position peaked at $145 in Q3 2023. 10 funds tracked by Wall St. Rank hold ENTX as of Q4 2023.

Stonebridge Capital Advisors reported no remaining Entera Bio position as of Q4 2023 after selling out during the quarter.
Stonebridge Capital Advisors sold 200 Entera Bio shares in Q4 2023, an estimated $145.
Stonebridge Capital Advisors first reported a position in Entera Bio in Q3 2023 and held it in 1 quarter.
Stonebridge Capital Advisors's Entera Bio position peaked at $145 in Q3 2023.
10 funds tracked by Wall St. Rank held Entera Bio as of Q4 2023.

Based on Stonebridge Capital Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.